1. Detection of specific antibodies to HCV-ARF/CORE+1 protein in patients treated with pegylated interferon plus ribavirin
- Author
-
Karamitros, T, Kakkanas, A, Katsoulidou, A, Sypsa, V, Dalagiorgou, G, Mavromara, P, and Hatzakis, A
- Subjects
Adult ,Male ,Viral Core Proteins ,virus diseases ,Interferon-alpha ,Hepacivirus ,Hepatitis C Antibodies ,Hepatitis C, Chronic ,Middle Aged ,Antiviral Agents ,digestive system diseases ,Recombinant Proteins ,Polyethylene Glycols ,Young Adult ,Ribavirin ,Escherichia coli ,Humans ,RNA, Viral ,Drug Therapy, Combination ,Female ,Aged - Abstract
Hepatitis C virus (HCV) infection is a major cause for chronic liver disease and hepatocellular carcinoma. The HCV-ARF/core+1 protein is an alternative product of HCV core-encoding sequence of unknown biological function. Highly purified HCV core and ARF/core+1 recombinant proteins from HCV genotype 1a and HCV-ARF/core+1 recombinant protein from HCV genotype 3a were expressed in Escherichia coli. Using an enzyme-linked immunosorbent assay, we assessed the prevalence of anti-ARF/core+1 antibodies in 90 chronic hepatitis C patients infected with HCV genotypes 1a/1b or 3a, treated with pegylated interferon (Peg-IFN-a-2a) plus ribavirin. Samples derived from 92 healthy blood donors were used as negative controls. All HCV-RNA-positive serum samples reacted with core 1a antigen, while 15 (37.5%) of 40 and 14 (28%) of 50 patients infected with HCV-1a/1b and HCV-3a, respectively, were found to have anti-ARF/core+1 antibodies into their serum before treatment initiation. These antibodies were persistently present during treatment follow-up and linked to elevated levels of HCV-RNA at baseline.
- Published
- 2018